The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
July 16th 2025
The biosimilar showed similar efficacy, pharmacokinetics, pharmacodynamics, safety, quality of life, and immunogenicity in patients with chronic spontaneous urticaria (CSU).
FDA Approves Second Drug Treatment for Polyneuropathy
October 6th 2018The FDA has approved Akcea Therapeutics' inotersen (Tegsedi), an antisense oligonucleotide that inhibits the production of the transthyretin protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More
Officials with NCPA Applaud Opioid Relief Package, Which President Expected to Sign
October 6th 2018HR 6—which was passed in the Senate on Wednesday and in the House of Representatives last week—instructs the Secretary of Health and Human Services to establish a technical expert panel to review quality measures regarding opioids and opioid use disorders.
Read More
FDA Approves Prophylactic Treatment for Individuals With Hemophilia A
October 4th 2018Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.
Read More
FDA Approves Antibacterial Treatment for Lung Disease Through Novel Pathway
September 29th 2018The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria in a limited population of patients with the disease who do not respond to conventional treatment.
Read More
FDA Approves First Treatment for Advanced Cutaneous Squamous Cell Carcinoma
September 29th 2018Officials with the FDA have approved cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.
Read More
Epilepsy Treatment Receives FDA Approval for Use in Children
September 29th 2018The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.
Read More
Herbal Medicine: Catch Potential Problems in Pregnant Women Early
September 28th 2018Pregnant women take herbal and natural products (HNPs) as alternatives to prescription medications, but, HNPs have active ingredients and drug interactions that can potentially cause harm to both the mother and her baby.
Read More